Treatment Pathway
Treatment of Myasthenia Gravis
Myasthenia gravis is an autoimmune neuromuscular disease causing fluctuating muscle weakness, typically worsening with activity. Antibodies against acetylcholine receptors at the neuromuscular junction impair signal transmission; treatment includes cholinesterase inhibitors and immunosuppressants.
AAN (American Academy of Neurology)ESN (European Academy of Neurology)NICE (UK)Movement Disorder SocietyEpilepsy Society
Managing Myasthenia Gravis effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Myasthenia Gravis can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Accurate diagnosis essential: neuroimaging (MRI preferred), EEG, CSF analysis as indicated
- ✓Monotherapy preferred for epilepsy before combination; balance efficacy vs. teratogenicity
- ✓Early migraine prophylaxis if >4 headache days/month or significant disability
- ✓Levodopa remains gold standard for Parkinson's motor symptoms
- ✓Stroke: thrombolysis within 4.5h; thrombectomy up to 24h in selected patients; early secondary prevention
What to Do Now
- Learn your personal risk factors for Myasthenia Gravis (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Myasthenia Gravis
- Use our AI symptom checker to assess whether your symptoms fit an early Myasthenia Gravis pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Myasthenia Gravis-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Non-Pharmacological Management
- •Lifestyle triggers: identify and avoid migraine triggers (irregular sleep, skipped meals, alcohol, bright light)
- •Sleep hygiene: critical for epilepsy control and migraine management
- •Physiotherapy and occupational therapy: for Parkinson's, post-stroke rehabilitation, multiple sclerosis
- •Speech and language therapy: post-stroke, Parkinson's, ALS
- •Cognitive rehabilitation for dementia and post-stroke cognitive impairment
- •Seizure first aid education for patients and carers
- •Mediterranean diet: associated with reduced dementia risk and improved post-stroke outcomes
Treatment Goals
🎯Seizure freedom in epilepsy: achieved in 70% with appropriate monotherapy
🎯Migraine: ≥50% reduction in headache days
🎯Parkinson's: maintaining motor function and quality of life; minimise motor fluctuations
🎯Stroke: disability limitation (mRS ≤2); recurrence prevention
🎯Dementia: preserve function and quality of life; caregiver support
Monitoring Parameters
- ◆Seizure diary: frequency, type, duration — key for epilepsy drug titration
- ◆Cognitive function: MMSE/MoCA annually in dementia and Parkinson's
- ◆Motor function scales: UPDRS for Parkinson's; EDSS for MS; mRS for stroke
- ◆Drug levels: essential for phenytoin, carbamazepine, valproate — and lithium in psychiatric comorbidity
- ◆MRI: new or progressive neurological symptoms; MS disease activity monitoring
- ◆LFTs, FBC: valproate (hepatotoxicity, thrombocytopenia); carbamazepine (agranulocytosis)
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Myasthenia Gravis — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Myasthenia Gravis combined with new relevant symptoms
- ⚠Sudden worsening of Myasthenia Gravis symptoms despite established treatment
Escalation Criteria
- →Status epilepticus: IV benzodiazepine, then anti-epileptic loading dose; ICU if refractory
- →Parkinson's motor fluctuations despite optimised oral therapy → LCIG, DBS, or apomorphine infusion consideration
- →MS relapse: high-dose IV methylprednisolone; assess for disease-modifying therapy escalation
- →Acute severe migraine / thunderclap headache → exclude subarachnoid haemorrhage (CT + LP)
Special Populations
Women of childbearing age: epilepsy — avoid valproate; folic acid supplementation; contraception interaction risk with enzyme-inducing AEDs
Elderly: lower starting doses for most neurological drugs; monitor for falls risk (antiepileptics, dopaminergics)
Children: age-specific drug licensing; developmental impact of antiepileptics; paediatric neurologist referral
Pregnancy: most neurological medications require risk-benefit assessment; specialist review essential
Clinical Insights
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →